TW258663B - - Google Patents

Info

Publication number
TW258663B
TW258663B TW082105967A TW82105967A TW258663B TW 258663 B TW258663 B TW 258663B TW 082105967 A TW082105967 A TW 082105967A TW 82105967 A TW82105967 A TW 82105967A TW 258663 B TW258663 B TW 258663B
Authority
TW
Taiwan
Application number
TW082105967A
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of TW258663B publication Critical patent/TW258663B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082105967A 1992-07-23 1993-07-27 TW258663B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Publications (1)

Publication Number Publication Date
TW258663B true TW258663B (zh) 1995-10-01

Family

ID=10719151

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105967A TW258663B (zh) 1992-07-23 1993-07-27

Country Status (9)

Country Link
EP (1) EP0651642A1 (zh)
JP (1) JPH07509456A (zh)
CN (1) CN1043610C (zh)
AU (1) AU4714393A (zh)
GB (1) GB9215633D0 (zh)
MX (1) MX9304435A (zh)
TW (1) TW258663B (zh)
WO (1) WO1994002150A1 (zh)
ZA (1) ZA935339B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
EP1404675B1 (en) * 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2005509603A (ja) * 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006094933A1 (en) 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
MX9304435A (es) 1994-04-29
JPH07509456A (ja) 1995-10-19
EP0651642A1 (en) 1995-05-10
CN1043610C (zh) 1999-06-16
CN1114880A (zh) 1996-01-17
WO1994002150A1 (en) 1994-02-03
ZA935339B (en) 1995-01-18
GB9215633D0 (en) 1992-09-09
AU4714393A (en) 1994-02-14

Similar Documents

Publication Publication Date Title
DE9200110U1 (zh)
DE9214505U1 (zh)
DE9200049U1 (zh)
DE9200239U1 (zh)
DE9200236U1 (zh)
DE9200064U1 (zh)
DE9200172U1 (zh)
DE9200205U1 (zh)
DE9200121U1 (zh)
DE9200188U1 (zh)
DE9200163U1 (zh)
DE9200215U1 (zh)
DE9200022U1 (zh)
DE9200243U1 (zh)
DE9200056U1 (zh)
DE9200256U1 (zh)
DE9200080U1 (zh)
DE9200154U1 (zh)
DE9200173U1 (zh)
DE9200294U1 (zh)
DE9200123U1 (zh)
DE9200131U1 (zh)
DE9200293U1 (zh)
DE9214895U1 (zh)
DE9200221U1 (zh)

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent